Q-omics provides the consensus-scored CEACAM21 profile across patient tissues and cancer cell-line models. CEACAM21 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CEACAM21 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CEACAM21 RNA expression shows 22,234 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CEACAM21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAM21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAM21 survival associations across molecular data types. CEACAM21 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAM21 RNA expression–survival associations across cancer types. High CEACAM21 expression shows favorable associations in HNSC, UCEC, SKCM, LUAD, CESC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CEACAM21 RNA expression.
This table summarizes CEACAM21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CEACAM21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAM21 shows lower tumor expression in LUSC, LUAD, KICH, UCEC and CHOL and higher tumor expression in KIRC. The KIRC box plot shows higher CEACAM21 RNA expression in tumor versus normal tissue (log2 FC = +1.304, t-test p < 0.001).
This table shows molecular features associated with CEACAM21 in patient tissues and cancer cell lines. In patient samples, CEACAM21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CEACAM21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
